Comparison of bone mineral density changes between denosumab and bisphosphonates in tenofovir-exposed chronic hepatitis B patients with osteoporosis
An erratum to this article was published (Osteoporos Int, Nov 2025 ↗)
Authors' conclusion
In TDF-exposed CHB patients with osteoporosis, denosumab outperformed bisphosphonates in the LS and FN BMD at year 1.
Study context
- Population
- Chronic hepatitis B (CHB) patients with newly diagnosed osteoporosis during > 1 year of tenofovir disoproxil fumarate (TDF) treatment, 2010–June 2024, two tertiary centers in Korea
- Participants
- 155 patients
- Exposure
- Denosumab vs bisphosphonates
- Denosumabn = 79
- Bisphosphonatesn = 76reference
- Outcome
- Bone mineral density (BMD) change in the lumbar spine (LS) and femoral neck (FN)
- Follow-up
- Year 1
Methodological detailspropensity score matching, inverse probability of treatment weighting, two tertiary centres
- Propensity score matching
- Inverse probability of treatment weighting
- Two tertiary centres
Main finding
As reported in the abstract
BMD change
LS
P = 0.001
FN
P = 0.008
Observational data: associations, not effects.
Secondary outcomes
| Outcome | Denosumab | Bisphosphonates | P value |
|---|---|---|---|
| P1NP change · 6 months | −72.7% | −63.8% | P = 0.001 |
| CTX change · 6 months | −70.8% | −71.4% | P = 0.74 |
CTX change · 6 months
- No significant difference in CTX changes
Original publication
Comparison of bone mineral density changes between denosumab and bisphosphonates in tenofovir-exposed chronic hepatitis B patients with osteoporosis. Osteoporos Int. Published 11 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →